bioAffinity Technologies Inc. Common Stock (BIAF)
Stock · NASDAQ · Health Care
$3.73as of 10/16/2026
Price chart
Active signals
BIAF Signal Track Record
How signals performed across all stocks →What BIAF's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 19 | -24.7% | 26% | October 8, 2026 |
| Bollinger Band Breakdown | 18 | -3.5% | 44% | August 13, 2026 |
| Bollinger Band Breakout | 13 | -11.2% | 31% | August 24, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -5.1% | 20% | October 9, 2024 |
| Any 20-session window (baseline) | -12.2% | 36% |
Computed by MarketWall from daily closing prices since June 20, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze…
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Employees
- 57
- Website
- bioaffinitytech.com/
Fundamentals
- 1-day range
- $3.8$4.75
- Market cap
- $4.12M
- P/E (trailing)
- —
- P/E (forward)
- -6.61
- EPS (trailing)
- $-6.89
- Dividend yield
- —
- Beta
- -1.28
- Avg. volume
- 3.68M
How bioAffinity Technologies Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 16, 2026 · via SEC EDGAR / Finnhub
bioAffinity Technologies Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BIAFbioAffinity Technologies Inc. Common Stock$3.73▼ 5.81%Market cap $4.12MP/E —$4.56$80.7
- ISPCiSpecimen Inc. Common Stock$0.917▼ 10.97%Market cap $3.35MP/E —$1.02$36.32
- ONMDOneMedNet Corp Class A Common Stock$4.51▼ 5.05%Market cap $37.18MP/E —$4.9$42.2
- MXCTMaxCyte Inc. Common Stock$1.3▲ 0.00%Market cap $118.91MP/E —$0.643$1.87
- OABIOmniAb Inc. Common Stock$4.59▼ 2.96%Market cap $324.74MP/E —$1.3$5.43
- NRCNRC Health Common Stock$20.15▼ 4.55%Market cap $430.67MP/E 79.70$11.01$23.68
- ABSIAbsci Corporation Common Stock$8.25▼ 7.09%Market cap $1.29BP/E —$2.24$12.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BIAF bioAffinity Technologies Inc. Common Stock | $4.12M | — | $3.73 | ▼ 5.81% | $4.56$80.7 |
| ISPC iSpecimen Inc. Common Stock | $3.35M | — | $0.917 | ▼ 10.97% | $1.02$36.32 |
| ONMD OneMedNet Corp Class A Common Stock | $37.18M | — | $4.51 | ▼ 5.05% | $4.9$42.2 |
| MXCT MaxCyte Inc. Common Stock | $118.91M | — | $1.3 | ▲ 0.00% | $0.643$1.87 |
| OABI OmniAb Inc. Common Stock | $324.74M | — | $4.59 | ▼ 2.96% | $1.3$5.43 |
| NRC NRC Health Common Stock | $430.67M | 79.70 | $20.15 | ▼ 4.55% | $11.01$23.68 |
| ABSI Absci Corporation Common Stock | $1.29B | — | $8.25 | ▼ 7.09% | $2.24$12.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · 9/11/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 211.1K
- Total value held
- $809.5K
- Institutional holders
- 13
- Unknown55.5K
- Unknown48.3K
- Unknown42.6K
- Unknown24.4K
- Unknown14.4K
- Unknown12.7K
- Unknown9.2K
- Unknown2.1K
- Unknown1.0K
- Unknown833
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
bioAffinity Partners with AvMEDICAL to Promote CyPath Lung Test
bioAffinity Technologies has teamed with veteran‑owned AvMEDICAL to raise awareness of its CyPath® lung cancer test. The two companies showcased the test together at a joint exhibition, highlighting its non‑invasive nature. The partnership is intended to expand access for veterans and build momentum for the technology.
bioAffinity Partners with AvMEDICAL to Promote CyPath Lung Test. bioAffinity Technologies has teamed with veteran‑owned AvMEDICAL to raise awareness of its CyPath® lung cancer test. The two companies showcased the test together at a joint exhibition, highlighting its non‑invasive nature. The partnership is intended to expand access for veterans and build momentum for the technology.